Azitra, Inc. (AZTR)
| Market Cap | 11.13M |
| Revenue (ttm) | 626,500 |
| Net Income (ttm) | -12.88M |
| Shares Out | 12.10M |
| EPS (ttm) | -1.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,440 |
| Open | 1.100 |
| Previous Close | 1.060 |
| Day's Range | 0.920 - 1.120 |
| 52-Week Range | 0.920 - 5.180 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 6, 2024 |
About AZTR
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggri... [Read more]
Financial Performance
Financial StatementsNews
Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported fi...
Azitra to Present at the ThinkEquity Conference
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced today t...
Azitra to Present at the H.C. Wainwright 25th Annual Global Investment Conference
BRANFORD, Conn., Aug. 29, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, anno...
Azitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates
BRANFORD, Conn. , Aug. 14, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors
BRANFORD, Conn. , July 19, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer
BRANFORD, Conn. , July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
Azitra, Inc. Announces Closing of Initial Public Offering
BRANFORD, Conn. , June 21, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) (the "Company"), a biopharmaceutical company focused on developing innovative therapies for precision dermatology usi...
Azitra, Inc. Announces Pricing of Initial Public Offering
BRANFORD, Conn. , June 15, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) (the "Company"), a biopharmaceutical company focused on developing innovative therapies for precision dermatology usi...
Azitra IPO Registration Document (S-1)
Azitra has filed to go public with an IPO on the NYSE American.